<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00461136</url>
  </required_header>
  <id_info>
    <org_study_id>CSPP100A2242</org_study_id>
    <nct_id>NCT00461136</nct_id>
  </id_info>
  <brief_title>Time Course of the Antiproteinuric and Blood Pressure Lowering Effects After Initiation of Renin Inhibition With Aliskiren in Type 2 Diabetes</brief_title>
  <official_title>An Open-label, One-period, One-treatment Study to Evaluate the Time Course of the Antiproteinuric and Blood Pressure Lowering Effects After Initiation of Renin Inhibition With Aliskiren in Type 2 Diabetes Suffering From Incipient and/or Established Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the time-course of the antiproteinuric effect of renin inhibition&#xD;
      with Aliskiren in patients with Type 2 diabetes suffering from incipient and/or established&#xD;
      nephropathy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the time-course of the antiproteinuric effect of renin inhibition with Aliskiren in patients with Type 2 diabetes suffering from incipient and/or established nephropathy.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To measure blood pressure changes over time during the onset and offset of effect.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate whether there is a change on biomarkers of inflammation and cardiovascular risk.</measure>
  </secondary_outcome>
  <enrollment>18</enrollment>
  <condition>Diabetes Type 2</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and/or female patients from 30-80 years of age with a diagnosis of Type 2&#xD;
             diabetes (WHO criteria).&#xD;
&#xD;
          -  Incipient and established diabetic nephropathy (urinary albumin excretion ≥ 100 mg/day&#xD;
             but ≤ 2000 mg/day).&#xD;
&#xD;
          -  Glomerular filtration rate (GFR) ≥ 40 ml/min (estimated using Modification of Diet in&#xD;
             Renal Disease (MDRD) formula) in the last 4 months.&#xD;
&#xD;
          -  Female patients must be postmenopausal or must have had a bilateral oophorectomy or&#xD;
             must have been surgically sterilized or hysterectomized at least 6 months prior to&#xD;
             screening.&#xD;
&#xD;
          -  To be eligible patients must fulfill the following criteria: Patients on ongoing&#xD;
             hypertensive therapy must have a blood pressure ≥ 135/85 mm Hg but lower than 170/105&#xD;
             mm Hg at baseline (Day -1) AND patients must be on stable antihypertensive medications&#xD;
             for at least 8 weeks prior to baseline (Day -1).; Newly diagnosed hypertensive&#xD;
             patients must have a blood pressure ≥ 135/85 mm Hg but lower than 170/105 mm Hg at&#xD;
             baseline (Day -1).&#xD;
&#xD;
          -  Patients must be on stable hypoglycemic medications for at least 8 weeks prior to&#xD;
             Visit 2 ( Day -1).&#xD;
&#xD;
          -  Patients must be willing and medically able to discontinue all Angiotensin-converting&#xD;
             enzyme inhibitor (ACEI), Angiotensin receptor blocker (ARB), aldosterone receptor&#xD;
             antagonist and potassium sparing diuretic medications for the duration of the study.&#xD;
&#xD;
          -  Oral body temperature within the range 35.0-37.5 °C&#xD;
&#xD;
          -  Able to provide written informed consent prior to study participation. .&#xD;
&#xD;
          -  Able to communicate well with the investigator and comply with the requirements of the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe Hypertension Grade 3 WHO classification (Mean Sitting Diastolic Blood Pressure&#xD;
             (MSDBP) 110 mmHg and/or Mean Sitting Systolic Blood Pressure MSSBP 180 mmHg)&#xD;
&#xD;
          -  Acetylsalicyclic acid (ASA) treatment &gt;1g/day or regular use of Non steroidal&#xD;
             anti-inflammatory drug (NSAIDs)&#xD;
&#xD;
          -  Kidney disease not caused by diabetes or hypertension&#xD;
&#xD;
          -  Serum potassium &lt; 3.5 or &gt; 5.1 mEq/L&#xD;
&#xD;
          -  GFR &lt; 40 ml/min/1.73m2 as measured by the MDRD formula&#xD;
&#xD;
          -  Serum albumin &lt; 2.0mg/dL&#xD;
&#xD;
          -  History of hypertensive encephalopathy or cerebrovascular accident at any time prior&#xD;
             to Visit1.&#xD;
&#xD;
          -  Current diagnosis of heart failure (New York Heart Association (NYHA) Class II-IV)&#xD;
&#xD;
          -  History of myocardial infarction, unstable angina pectoris, coronary bypass surgery,&#xD;
             or any percutaneous coronary intervention (PCI) during the 6 months prior to Visit 1&#xD;
&#xD;
          -  Second or third degree heart block without a pacemaker&#xD;
&#xD;
          -  Concurrent potentially life threatening arrhythmia or symptomatic arrhythmia&#xD;
&#xD;
          -  Clinically significant valvular heart disease&#xD;
&#xD;
          -  Type 1 diabetes mellitus&#xD;
&#xD;
          -  Uncontrolled Type II diabetes mellitus (Hemaglobin subtype A1C (HbA1C) &gt;11 %)&#xD;
&#xD;
          -  History of malignancy including leukemia and lymphoma (but not basal cell skin&#xD;
             carcinoma) within the past five years&#xD;
&#xD;
          -  Participation in any clinical investigation within 4 weeks prior to dosing or longer&#xD;
             if required by local regulation.&#xD;
&#xD;
          -  Donation or loss of 400 mL or more of blood within 8 weeks prior to dosing.&#xD;
&#xD;
          -  Significant illness within the two weeks prior to dosing.&#xD;
&#xD;
          -  Any surgical or medical condition which might significantly alter the absorption,&#xD;
             distribution, metabolism, or excretion of study drugs including, but not limited to,&#xD;
             any of the following:&#xD;
&#xD;
        History of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or&#xD;
        bowel resection&#xD;
&#xD;
        -Currently active or previously active inflammatory bowel disease during the 12 months&#xD;
        prior to Visit 1 Currently active gastritis, duodenal or gastric ulcers, or&#xD;
        gastrointestinal/rectal bleeding during the 3 months prior to Visit 1.&#xD;
&#xD;
        Any history of pancreatic injury, pancreatitis or evidence of impaired pancreatic&#xD;
        function/injury as indicated by abnormal lipase or amylase Evidence of hepatic disease, a&#xD;
        history of hepatic encephalopathy, a history of esophageal varices, or a history of&#xD;
        portocaval shunt&#xD;
&#xD;
          -  Current treatment with cholestyramine or cholestipol resins&#xD;
&#xD;
          -  History of immunocompromise, including a positive HIV test result.&#xD;
&#xD;
          -  History of a positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result.&#xD;
&#xD;
          -  History of drug or alcohol abuse within the 12 months prior to dosing.&#xD;
&#xD;
          -  Persons directly involved in the execution of this protocol.&#xD;
&#xD;
          -  Any condition that in the opinion of the investigator or the Novartis medical monitor&#xD;
             would jeopardize the evaluation of efficacy or safety&#xD;
&#xD;
          -  History of noncompliance to medical regimens or unwillingness to comply with the study&#xD;
             protocol&#xD;
&#xD;
          -  Known or suspected contraindications to the study medications, including history of&#xD;
             allergy to Angiotensin converting enzyme (ACE) inhibitors and/or to thiazide diuretics&#xD;
             or other sulfonamide derived drug&#xD;
&#xD;
          -  Any surgical or medical condition, which in the opinion of the investigator, may place&#xD;
             the patient at higher risk from his/her participation in the study, or is likely to&#xD;
             prevent the patient from complying with the requirements of the study or completing&#xD;
             the study&#xD;
&#xD;
          -  Use of any prescription drug or over-the-counter (OTC) medication which is prohibited&#xD;
             by the protocol.&#xD;
&#xD;
          -  Patients who previously participated in any Aliskiren study.&#xD;
&#xD;
          -  Pregnant or nursing woman.&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Investigative site</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Gentofte</city>
        <zip>2820</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>April 16, 2007</study_first_submitted>
  <study_first_submitted_qc>April 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2007</study_first_posted>
  <last_update_submitted>September 22, 2016</last_update_submitted>
  <last_update_submitted_qc>September 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2016</last_update_posted>
  <keyword>Time course</keyword>
  <keyword>antiproteinuric</keyword>
  <keyword>blood pressure</keyword>
  <keyword>lowering effect</keyword>
  <keyword>initiation of renin inhibition</keyword>
  <keyword>Aliskiren in Type 2 diabetes</keyword>
  <keyword>incipient and/or established nephropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

